• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接受全髋关节置换术的病态肥胖患者中,早期不良结局仍然难以预防。

Early adverse outcomes remain challenging to prevent in morbidly obese patients undergoing total hip arthroplasty.

机构信息

Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Bone Joint J. 2024 Nov 1;106-B(11):1223-1230. doi: 10.1302/0301-620X.106B11.BJJ-2023-1187.R1.

DOI:10.1302/0301-620X.106B11.BJJ-2023-1187.R1
PMID:39481442
Abstract

AIMS

The prevalence of obesity is increasing substantially around the world. Elevated BMI increases the risk of complications following total hip arthroplasty (THA). We sought to evaluate trends in BMI and complication rates of obese patients undergoing primary THA over the last 30 years.

METHODS

Through our institutional total joint registry, we identified 15,455 primary THAs performed for osteoarthritis from 1990 to 2019. Patients were categorized according to the World Health Organization (WHO) obesity classification and groups were trended over time. Cox proportional hazards regression analysis controlling for confounders was used to investigate the association between year of surgery and two-year risk of any reoperation, any revision, dislocation, periprosthetic joint infection (PJI), venous thromboembolism (VTE), and periprosthetic fracture. Regression was stratified by three separate groups: non-obese; WHO Class I and Class II (BMI 30 to 39 kg/m); and WHO Class III patients (BMI ≥ 40 kg/m).

RESULTS

There was a significant increase in the proportion of all obesity classes from 1990 to 2019, and the BMI values within each WHO class significantly increased over time. Risk of any reoperation did not change over time among non-obese or WHO Class I/II patients, but increased for WHO Class III patients (hazard ratio (HR) 1.04; p = 0.044). Risk of dislocation decreased over time for non-obese (HR 0.96; p < 0.001) and WHO Class I/II (HR 0.96; p = 0.002) patients, but did not change over time for WHO Class III (HR 0.94; p = 0.073) patients. Risks of any revision and PJI did not change over time for any group.

CONCLUSION

The proportion of patients undergoing THA who are obese has increased dramatically at our institution between 1990 and 2019. Despite BMI values increasing within all WHO classes over time, two-year complication risks have remained stable or decreased in WHO Class I/II patients. However, continued efforts will be required to mitigate risks in the heaviest WHO Class III patients.

摘要

目的

肥胖在全球范围内呈显著上升趋势。升高的 BMI 增加了全髋关节置换术后(THA)发生并发症的风险。我们旨在评估过去 30 年来,超重患者接受初次 THA 的 BMI 趋势和并发症发生率。

方法

通过我们的机构全关节登记处,我们确定了 1990 年至 2019 年间因骨关节炎接受初次 THA 的 15455 例患者。根据世界卫生组织(WHO)肥胖分类对患者进行分类,并随时间推移对各分组进行趋势分析。采用 Cox 比例风险回归分析控制混杂因素,调查手术年份与两年内任何再手术、任何翻修、脱位、假体周围关节感染(PJI)、静脉血栓栓塞(VTE)和假体周围骨折的风险之间的关联。回归分析分层为三个独立的分组:非肥胖;WHO 分类 I 和 II(BMI 为 30 至 39kg/m²);和 WHO 分类 III 患者(BMI≥40kg/m²)。

结果

从 1990 年到 2019 年,所有肥胖类别的比例显著增加,每个 WHO 类别内的 BMI 值随时间推移显著增加。非肥胖或 WHO I/II 患者中,任何再手术的风险随时间推移没有变化,但 WHO III 患者的风险增加(风险比(HR)为 1.04;p=0.044)。非肥胖(HR 0.96;p<0.001)和 WHO I/II(HR 0.96;p=0.002)患者的脱位风险随时间推移而降低,但 WHO III(HR 0.94;p=0.073)患者的脱位风险随时间推移没有变化。任何翻修和 PJI 的风险在任何分组中都没有随时间变化。

结论

在我们的机构中,1990 年至 2019 年间,接受 THA 的肥胖患者比例大幅增加。尽管所有 WHO 类别内的 BMI 值随时间推移而增加,但 WHO I/II 患者的两年并发症风险保持稳定或降低。然而,仍需要继续努力降低最重的 WHO III 类患者的风险。

相似文献

1
Early adverse outcomes remain challenging to prevent in morbidly obese patients undergoing total hip arthroplasty.在接受全髋关节置换术的病态肥胖患者中,早期不良结局仍然难以预防。
Bone Joint J. 2024 Nov 1;106-B(11):1223-1230. doi: 10.1302/0301-620X.106B11.BJJ-2023-1187.R1.
2
Outcomes of Obese Patients Undergoing Primary Total Knee Arthroplasty: Trends Over 30 Years.肥胖患者初次全膝关节置换术的结局:30 年趋势。
J Bone Joint Surg Am. 2024 Nov 6;106(21):1963-1970. doi: 10.2106/JBJS.23.01413. Epub 2024 Sep 24.
3
Ten-year risk of complication and mortality after total hip arthroplasty in morbidly obese patients: a population study.肥胖患者全髋关节置换术后十年并发症和死亡率的风险:一项人群研究。
Can J Surg. 2019 Dec 1;62(6):442-449. doi: 10.1503/cjs.017318.
4
Increasing Body Mass Index Not Associated With Worse Patient-Reported Outcomes After Primary THA or TKA.体重指数增加与初次全髋关节置换术或全膝关节置换术后患者报告的较差预后无关。
J Am Acad Orthop Surg. 2025 Jan 15;33(2):e114-e123. doi: 10.5435/JAAOS-D-24-00154. Epub 2024 May 22.
5
Surgical Risks and Costs of Care are Greater in Patients Who Are Super Obese and Undergoing THA.超级肥胖且正在接受全髋关节置换术的患者,手术风险和护理成本更高。
Clin Orthop Relat Res. 2016 Nov;474(11):2472-2481. doi: 10.1007/s11999-016-5039-1. Epub 2016 Aug 25.
6
Super Obesity Is an Independent Risk Factor for Complications After Primary Total Hip Arthroplasty.超级肥胖是初次全髋关节置换术后并发症的独立危险因素。
J Arthroplasty. 2017 Feb;32(2):402-406. doi: 10.1016/j.arth.2016.08.001. Epub 2016 Aug 9.
7
Super-obese patients are associated with significant infection burden after total hip arthroplasty.超级肥胖患者在全髋关节置换术后存在显著的感染负担。
Hip Int. 2023 Sep;33(5):806-811. doi: 10.1177/11207000221144740. Epub 2023 Jan 26.
8
The Use of Aspirin for Venous Thromboembolism Prophylaxis in Patients Who Have Morbid Obesity Undergoing Primary and Revision Total Joint Arthroplasty.在接受初次和翻修全关节置换术的病态肥胖患者中,阿司匹林用于静脉血栓栓塞预防。
J Arthroplasty. 2024 Oct;39(10):2413-2420. doi: 10.1016/j.arth.2024.05.053. Epub 2024 May 24.
9
Increased Risk of 10-Year Revision Following Total Hip Arthroplasty for Femoral Neck Fracture.股骨颈骨折全髋关节置换术后10年翻修风险增加。
J Arthroplasty. 2025 Mar;40(3):688-692. doi: 10.1016/j.arth.2024.09.012. Epub 2024 Sep 14.
10
The Association of Body Mass Index with Risk of Long-Term Revision and 90-Day Mortality Following Primary Total Hip Replacement: Findings from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man.体重指数与初次全髋关节置换术后长期翻修风险和 90 天死亡率的关系:来自英格兰、威尔士、北爱尔兰和马恩岛国家联合登记处的研究结果。
J Bone Joint Surg Am. 2018 Dec 19;100(24):2140-2152. doi: 10.2106/JBJS.18.00120.

引用本文的文献

1
Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.黄连素作为肥胖症的多靶点治疗药物:从药理机制到临床证据
Eur J Med Res. 2025 Jun 12;30(1):477. doi: 10.1186/s40001-025-02738-6.